Hanieh Hossein Nejad Ariani

Dr. Hanieh Hossein Nejad Ariani

Polypeptide Group, Torrance, California, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
HAHanieh Hossein Nejad Ariani
Hanieh Hossein Nejad Ariani
TKTushar Kim
Tushar Kim
Kamaljit KaurKamaljit Kaur
Kamaljit Kaur

21 February 2013 in Inorganic Chemistry
Verified
Journal Article
Closed access
HAHanieh Hossein Nejad Ariani
Hanieh Hossein Nejad Ariani
APAgnieszka Polkowska-Nowakowska
Agnieszka Polkowska-Nowakowska
Wojciech BalWojciech Bal
Wojciech Bal

1 October 2013 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
APAnna Maria Protas
Anna Maria Protas
HAHanieh Hossein Nejad Ariani
Hanieh Hossein Nejad Ariani
ABArkadiusz Bonna
Arkadiusz Bonna
APAgnieszka Polkowska-Nowakowska
Agnieszka Polkowska-Nowakowska
JPJarosław Poznański
Jarosław Poznański
Wojciech BalWojciech Bal
Wojciech Bal

1 July 2021 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
HKHirotaka Kanzaki
Hirotaka Kanzaki
ACAvradip Chatterjee
Avradip Chatterjee
HAHanieh Hossein Nejad Ariani
Hanieh Hossein Nejad Ariani
XZXinfeng Zhang
Xinfeng Zhang
SCStacey Chung
Stacey Chung
RMRamachandran Murali
Ramachandran Murali
Introduction: Constitutive activation of NF-κB has been implicated as being contributive to cancer cell growth, drug resistance, and tumor recurrence in many cancers including breast cancer. Activation of NF-κB leads to nuclear translocation of RelA, a critical component of the NF-κB transcription factor complex, which subsequently binds to specific DNA sites and activates a multitude of genes involved in diverse cell functions. Studies show that triple-negative breast cancer (TNBC) cells possess constitutively active NF-κB and concomitantly have higher levels of nuclear localization of RelA than cytoplasmic RelA. This feature is considered to be associated with the response to chemotherapy. However, currently, there is no specific inhibitor to block nuclear translocation of RelA. Methods: A structure-based approach was used to develop a small-molecule inhibitor of RelA nuclear translocation. The interaction between this molecule and RelA was verified biophysically through isothermal titration calorimetry and microscale thermophoresis. TNBC cell lines MDA-MB-231 and MDA-MB-468 and a human TNBC xenograft model were used to verify in vitro and in vivo efficacy of the small molecule, respectively. Results: We found that the small molecule, CRL1101, bound specifically to RelA as indicated by the biophysical assays. Further, CRL1101 blocked RelA nuclear translocation in breast cancer cells in vitro, and markedly reduced breast tumor growth in a triple-negative breast cancer xenograft model. Conclusion: Our study demonstrates that CRL1101 may lead to new NF-κB-targeted therapeutics for TNBC. Further, blocking of nuclear translocation of shuttling transcription factors may be a useful general strategy in cancer drug development.

11 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
STShirley Tong
Shirley Tong
SDShaban Darwish
Shaban Darwish
HAHanieh Hossein Nejad Ariani
Hanieh Hossein Nejad Ariani
KLKate Alison Lozada
Kate Alison Lozada
David SalehiDavid Salehi
David Salehi
SYSun (Coco) Yang
Sun (Coco) Yang
Melanoma is the most fatal type of skin cancer and is notoriously resistant to chemotherapies. The response of melanoma to current treatments is difficult to predict. To combat these challenges, in this study, we utilize a small peptide to increase drug delivery to melanoma cells. A peptide library array was designed and screened using a peptide array-whole cell binding assay, which identified KK-11 as a novel human melanoma-targeting peptide. The peptide and its D-amino acid substituted analogue (VPWxEPAYQrFL or D-aa KK-11) were synthesized via a solid-phase strategy. Further studies using FITC-labeled KK-11 demonstrated dose-dependent uptake in human melanoma cells. D-aa KK-11 significantly increased the stability of the peptide, with 45.3% remaining detectable after 24 h with human serum incubation. Co-treatment of KK-11 with doxorubicin was found to significantly enhance the cytotoxicity of doxorubicin compared to doxorubicin alone, or sequential KK-11 and doxorubicin treatment. In vivo and ex vivo imaging revealed that D-aa KK-11 distributed to xenografted A375 melanoma tumors as early as 5 min and persisted up to 24 h post tail vein injection. When co-administered, D-aa KK-11 significantly enhanced the anti-tumor activity of a novel nNOS inhibitor (MAC-3-190) in an A375 human melanoma xenograft mouse model compared to MAC-3-190 treatment alone. No apparent systemic toxicities were observed. Taken together, these results suggest that KK-11 may be a promising human melanoma-targeted delivery vector for anti-melanoma cargo.